首页> 外文期刊>International journal of colorectal disease. >Sodium hyaluronate-based bioresorbable membrane (Seprafilm((R))) reduced early postoperative intestinal obstruction after lower abdominal surgery for colorectal cancer: the preliminary report.
【24h】

Sodium hyaluronate-based bioresorbable membrane (Seprafilm((R))) reduced early postoperative intestinal obstruction after lower abdominal surgery for colorectal cancer: the preliminary report.

机译:基于透明质酸钠的生物可吸收膜(Seprafilm(R))减少了大肠癌的下腹部手术后术后早期肠梗阻:初步报告。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSES: This study is a prospective randomized clinical trial to evaluate the clinical safety and the effect of a sodium hyaluronate-based bioresorbable membrane (Seprafilm(R); Genzyme, Cambridge, MA, USA) for reducing adhesive intestinal obstruction after colorectal cancer surgery. MATERIALS AND METHODS: Between November 2002 and December 2003, 504 patients underwent radical resection for sigmoid or rectal cancer. Among these patients, 427 patients were enrolled in this study. The patients were randomized into the Seprafilm(R) group (N = 185) and the control group (N = 242). All the patients in the Seprafilm(R) group received one sheet of Seprafilm(R) over the pelvic inlet where the peritoneum was denuded due to pelvic dissection. Intestinal obstruction was defined when there were symptoms of nausea, vomiting, and abdominal distension combined with an obstructive bowel pattern on the radiologic evaluation. RESULTS: The median follow-up period was 25.0 months. There were no significant differences between the Seprafilm(R) and the control groups for the clinicopathologic parameters. There were no differences in the incidence of complications between the two groups; however, the incidence of early postoperative intestinal obstruction was significantly less in the Seprafilm(R) group than in the control group (2.7% vs 7.0%, respectively, p = 0.045). Five patients in the Seprafilm(R) group experienced postoperative intestinal obstruction (2.7%) compared with 11 patients in the control group (4.6%) during the follow-up period; however, there was no statistical difference. CONCLUSIONS: Seprafilm(R) appears to be effective in preventing early postoperative intestinal obstruction and there was a trend for reduced intestinal obstruction after lower abdominal surgery for colorectal cancer.
机译:目的:本研究是一项前瞻性随机临床试验,旨在评估基于透明质酸钠的生物可吸收膜(Seprafilm(R); Genzyme,Cambridge,MA,USA)减少结直肠癌手术后粘连性肠梗阻的临床安全性和效果。材料与方法:在2002年11月至2003年12月之间,有504例患者因乙状结肠或直肠癌接受了根治性切除术。在这些患者中,本研究招募了427名患者。将患者随机分为Seprafilm(R)组(N = 185)和对照组(N = 242)。 Seprafilm(R)组的所有患者在盆腔入口处接受了一张Seprafilm(R),由于盆腔解剖,腹膜被剥夺。在放射学评估中,当出现恶心,呕吐和腹胀症状并伴有肠梗阻症状时定义为肠梗阻。结果:中位随访期为25.0个月。在Seprafilm(R)和对照组之间,临床病理参数没有显着差异。两组之间并发症的发生率没有差异。然而,Seprafilm(R)组术后早期肠梗阻的发生率明显低于对照组(分别为2.7%和7.0%,p = 0.045)。在随访期间,Seprafilm(R)组中有5例患者发生了肠梗阻(2.7%),而对照组中有11例(4.6%)。但是,没有统计学差异。结论:Seprafilm(R)似乎可有效预防术后早期肠梗阻,并且有下腹部手术治疗结直肠癌后肠梗阻减少的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号